Leukemia News

In this video, Rosalie Griffin, PhD, discusses the results of a study she presented at ESMO Congress 2024, which examined a biomarker that could indicate a person’s risk for developing blood cancer.

A meta-analysis of patients who underwent chimeric antigen receptor T-cell therapy for advanced blood cancers showed low prevalence of cardiovascular adverse events.

In this video, Naval Daver, MD, discusses a presentation on updates in immune and cellular therapy in acute myeloid leukemia from Society of Hematologic Oncology Annual Meeting.

Healio spoke with Naval Daver, MD, about a debate on the best duration of venetoclax in combination with azacitidine among older patients with acute myeloid leukemia from Society of Hematologic Oncology Annual Meeting.

Older adults diagnosed with a blood cancer exhibited similar rates of cognitive decline as cancer-free controls, according to study results.

Healio spoke with Naval Daver, MD, about presentations on the use of molecular therapies, including menin inhibitors, in the treatment of acute myeloid leukemia from Society of Hematologic Oncology Annual Meeting.

Older cancer survivors exhibited increased risk for cardiovascular disease than cancer-free individuals of the same age, according to a secondary analysis of a randomized study.

Patients who received chimeric antigen receptor T-cell therapy did not exhibit increased risk for second primary malignancies compared with those who received other standard treatments, according to a systematic review and meta-analysis.

Many patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma do not undergo immunoglobulin G testing despite its potential to reduce likelihood of severe infections.

Laurie H. Glimcher, MD, announced her intention to step down as president and CEO of Dana-Farber Cancer Institute on Oct. 1.